» Articles » PMID: 36984002

ZJUSAH Classification: A New Classification for Primary Brainstem Hemorrhage

Overview
Journal Life (Basel)
Specialty Biology
Date 2023 Mar 29
PMID 36984002
Authors
Affiliations
Soon will be listed here.
Abstract

To analyze and improve ZJUSAH classification for primary brainstem hematoma, we retrospectively reviewed 211 patients with primary brainstem hemorrhage who were admitted to our institution between January 2014 and October 2020. The primary clinical outcomes were the 30-day survival rate and 90-day consciousness recovery rate, which were evaluated using the National Institutes of Health Stroke Scale score. Univariate logistic regression and multivariate Cox regression analyses were performed to evaluate the prognostic model. The overall 30-day survival rate of the 211 patients was 69.7%. The 30-day survival rate was 95% among Type 1 patients, 77.8% among Type 2 patients, and 63.2% among Type 3 patients. The 90-day consciousness recovery rate was 63.2% among Type 1 patients, 61.9% among Type 2 patients, and 30.2% among Type 3 patients. Our findings suggest that ZJUSAH classification can be optimized according to hematoma volume, with Type 3 patients with a hematoma larger than 12.4 mL tending to have a worse state of consciousness. Additionally, we discovered that ZJUSAH classification is valuable in predicting 30-day survival rates in conservative treatment patients. In conclusion, our study established and optimized a new CT-based hematoma classification system for primary brainstem hematoma, which facilitates treatment selection and prognostic prediction.

Citing Articles

Development and validation of a prognostic nomogram for predicting outcomes in brainstem hemorrhage patients.

Wei S, Gu L, Fan Y, Ji P, Yang L, Li F Sci Rep. 2025; 15(1):1300.

PMID: 39779767 PMC: 11711512. DOI: 10.1038/s41598-024-80264-x.


Analysis of anti-infective therapy in a challenging case of brainstem hemorrhage complicated with pneumonia.

Wu T, Meng X, Chen N, Wang H, Yang H Heliyon. 2024; 10(24):e40988.

PMID: 39735627 PMC: 11681860. DOI: 10.1016/j.heliyon.2024.e40988.


Vascular Diseases: Etiologic, Diagnostic, Prognostic, and Therapeutic Research.

Olinic D, Stanek A Life (Basel). 2023; 13(5).

PMID: 37240816 PMC: 10224078. DOI: 10.3390/life13051171.

References
1.
Broderick J . The STICH trial: what does it tell us and where do we go from here?. Stroke. 2005; 36(7):1619-20. DOI: 10.1161/01.STR.0000170714.43167.34. View

2.
Wessels T, Moller-Hartmann W, Noth J, Klotzsch C . CT findings and clinical features as markers for patient outcome in primary pontine hemorrhage. AJNR Am J Neuroradiol. 2004; 25(2):257-60. PMC: 7974614. View

3.
Matsukawa H, Shinoda M, Fujii M, Takahashi O, Murakata A . Risk factors for mortality in patients with non-traumatic pontine hemorrhage. Acta Neurol Scand. 2014; 131(4):240-5. DOI: 10.1111/ane.12312. View

4.
Hemphill 3rd J, Greenberg S, Anderson C, Becker K, Bendok B, Cushman M . Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015; 46(7):2032-60. DOI: 10.1161/STR.0000000000000069. View

5.
Takahama H, Morii K, Sato M, Sekiguchi K, Sato S . [Stereotactic aspiration in hypertensive pontine hemorrhage: comparative study with conservative therapy]. No Shinkei Geka. 1989; 17(8):733-9. View